S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
S&P 500   3,337.59 (-1.06%)
DOW   28,914.06 (-1.05%)
QQQ   231.39 (-1.44%)
AAPL   316.84 (-1.08%)
FB   210.91 (-1.71%)
MSFT   180.39 (-2.19%)
GOOGL   1,502.44 (-0.96%)
AMZN   2,113.89 (-1.82%)
CGC   22.13 (-0.81%)
NVDA   297.45 (-3.64%)
MU   57.37 (-2.76%)
TSLA   888.68 (-1.19%)
AMD   55.21 (-3.60%)
T   38.51 (-0.26%)
ACB   1.66 (-1.19%)
F   7.93 (-1.25%)
NFLX   381.60 (-1.14%)
PRI   132.73 (-2.69%)
DIS   139.02 (-0.96%)
GILD   68.81 (+2.70%)
Log in

NASDAQ:GTHX - G1 Therapeutics Stock Price, Forecast & News

$17.74
-0.70 (-3.80 %)
(As of 02/21/2020 10:43 AM ET)
Today's Range
$17.51
Now: $17.74
$18.58
50-Day Range
$19.05
MA: $22.62
$26.43
52-Week Range
$13.87
Now: $17.74
$41.80
Volume75,648 shs
Average Volume207,404 shs
Market Capitalization$666.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$9.65 per share

Profitability

Net Income$-85,290,000.00

Miscellaneous

Employees84
Market Cap$666.67 million
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.


G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics Inc (NASDAQ:GTHX) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.01. View G1 Therapeutics' Earnings History.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for G1 Therapeutics.

How can I listen to G1 Therapeutics' earnings call?

G1 Therapeutics will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for GTHX?

7 analysts have issued 1 year price objectives for G1 Therapeutics' shares. Their forecasts range from $45.00 to $82.00. On average, they anticipate G1 Therapeutics' stock price to reach $67.17 in the next twelve months. This suggests a possible upside of 280.1% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.

What is the consensus analysts' recommendation for G1 Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.

What are Wall Street analysts saying about G1 Therapeutics stock?

Here are some recent quotes from research analysts about G1 Therapeutics stock:
  • 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (1/8/2020)
  • 2. HC Wainwright analysts commented, "We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.93/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48." (9/11/2019)

Has G1 Therapeutics been receiving favorable news coverage?

Media stories about GTHX stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. G1 Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for G1 Therapeutics.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 4,080,000 shares, a decline of 13.7% from the December 31st total of 4,730,000 shares. Based on an average daily volume of 324,600 shares, the days-to-cover ratio is presently 12.6 days. Currently, 13.5% of the company's stock are short sold. View G1 Therapeutics' Current Options Chain.

Who are some of G1 Therapeutics' key competitors?

What other stocks do shareholders of G1 Therapeutics own?

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the folowing people:
  • Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
  • Mr. James Stillman Hanson, Gen. Counsel (Age 47)
  • Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
  • Mr. John Demaree, Chief Commercial Officer (Age 52)
  • Ms. Jennifer K. Moses, Chief Financial Officer (Age 44)

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (3.66%), Geode Capital Management LLC (1.11%), Candriam Luxembourg S.C.A. (0.96%), Bank of America Corp DE (0.72%) and Rhenman & Partners Asset Management AB (0.70%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.

Which institutional investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Goldman Sachs Group Inc., UBS Group AG, Signaturefd LLC, Citigroup Inc., Rafferty Asset Management LLC, TD Asset Management Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for G1 Therapeutics.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Candriam Luxembourg S.C.A., Barclays PLC, Tang Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Marshall Wace LLP, Williams Jones Wealth Management LLC. and Alpine Global Management LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson and John Demaree. View Insider Buying and Selling for G1 Therapeutics.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $17.67.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $664.04 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is http://www.g1therapeutics.com/.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]


MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  240 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  495
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Price-Sales Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel